Physician profile
Anna Wendel
NPI 1437703675
$3,476.92
in general payments reported to CMS, 2019-2025
28 companies · $744 in 2025
The $744 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82.31 · 2022: $522 · 2023: $1,848 · 2024: $280 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,338 · Travel and Lodging: $401 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,338.40 |
| Travel and Lodging | $401.28 |
| Education | $133.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $1,063.43 | 2023-2024 | Ha Minuteman G3-R |
| Nevro Corp. | $530.75 | 2023 | Senza |
| Abbvie INC. | $210.54 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $205.12 | 2022-2025 | |
| Medtronic, INC. | $175.92 | 2022-2024 | Synchromedii, Intellis Adaptivestim |
| Regeneron Healthcare Solutions, INC. | $165.82 | 2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $160.00 | 2022-2025 | Airsupra, Tezspire, Daliresp |
| Ars Pharmaceuticals Operations, INC. | $130.94 | 2025 | Neffy |
| Glaxosmithkline, LLC. | $97.05 | 2021-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $94.29 | 2022 | |
| Relievant Medsystems, INC. | $76.77 | 2023 | Intracept |
| Biotronik Nro, INC. | $68.89 | 2023 | Biotronik |
| Spr Therapeutics, INC | $68.41 | 2023 | Sprint Pns System |
| Collegium Pharmaceutical, INC. | $64.90 | 2023-2024 | Belbuca, Xtampza |
| Optinose US, INC. | $55.04 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.56 | 2021-2022 | |
| Lilly USA, LLC | $31.75 | 2022 | |
| Vertos Medical, INC. | $30.22 | 2023 | Mild Device Kit |
| Sanofi-Aventis U.S. LLC | $29.63 | 2022 | |
| Painteq LLC | $26.90 | 2023 | Painteq |
| Alk-Abello, INC | $23.72 | 2025 | Odactra, Grastek, Ragwitek |
| Paratek Pharmaceuticals, INC. | $19.94 | 2025 | Xhance |
| Genzyme Corporation | $19.62 | 2025 | |
| Organon LLC | $17.69 | 2025 | |
| Novo Nordisk INC | $17.60 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.11 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.07 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $13.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Wendel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.